Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?Zacks Investment Research • 03/11/23
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023Business Wire • 03/09/23
Bristol-Myers Squibb Company (BMY) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/07/23
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)Business Wire • 03/03/23
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta ThalassemiaBusiness Wire • 03/03/23
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa InhibitorBusiness Wire • 03/02/23
Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care ConferenceBusiness Wire • 02/28/23
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of CardiologyBusiness Wire • 02/27/23
Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 TrialBusiness Wire • 02/17/23
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?Investors Business Daily • 02/17/23
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its SymptomsBusiness Wire • 02/16/23
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaBusiness Wire • 02/13/23
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 StudyBusiness Wire • 02/10/23